



## aktaPD: an Action-oriented Approach to Pharmaceutical Development

### Venture Capital: aktaPD Looks at the Risks and Rewards of Pre-Clinical Investment

**Christopher Columbus said, you can never cross the ocean until you have the courage to lose sight of the shore. But, a ship in a harbor is a safe ship.**

Face it, in a world where private financing for innovative therapeutic start-ups has been declining since 2006, it can be hard to justify sinking money into a new company...especially if the money just keeps right on sinking, straight to the bottom. It's easy to understand why venture capitalists may be unwilling to take that step off of terra firma into the unknown deep waters of investing in a new venture. How do you navigate the stormy seas of today's research marketplace and find the real treasure? Without the proper guidance and professional insight, it can feel like walking the plank blindfolded.

**But, in this business climate, it's also too risky to take no risks at all. So, why not go out on a limb? That's where the fruit is.**

Venture capital is paying off big in the world of medicine with a number of exciting developments including experimental lupus therapy, groundbreaking treatments for cancer and infectious diseases, innovative stem cell technologies and advanced healthcare IT solutions. And there are exciting developments in the VC world as well. Some companies are using big data to identify start-ups to watch. One company is even using an algorithm to create a Who's Who of budding entrepreneurs. Their formula predicts which shooting stars in the IT and medical worlds are most likely to launch a start-up. So, why are some VC companies succeeding with their investments and others not? It can be a tricky balancing act: if you've been burned before you can be gun-shy – for good reason. But, you can also be missing out on some amazing opportunities that are, well, ripe for the picking. How do you choose? How do you learn to trust again? The key is excellent guidance from seasoned professionals with a proven track record.

According to **aktaPD's** Anders Tamsen, MD PhD., a medical professional with more than 30 years of experience in clinical trials with

medical products under development including regulatory affairs and project management, the time is ripe for investment in some key areas of research. “We’ve seen how in the past the pharma industry has made great contributions in the cardiovascular field and I’m hoping soon to see similar progress in CNS diseases,” said Dr. Tamsen. “As our population ages, diseases of the central nervous system such as Alzheimer’s, Parkinson’s, and stroke will be quite costly to society and its consequences must be given more attention. I don’t think progress will come only in the form of new medicines but also as new diagnostic procedures and training of the elderly and care providers.” Dr. Tamsen forecasts a rich scientific harvest – ultimately benefitting patients – thanks in large part to the support of funding organizations. “These are exciting times we live in,” he concludes. “I believe we will soon understand how to treat diabetes and obesity more effectively than we do today because that’s an area where a lot of companies and academic research groups are involved. And I also believe we’ll find effective treatments for some forms of cancer in the application of nano medicine.”



**Interested in the next big adventure?** Need help making sound VC choices? Ready for an action-oriented approach to pharmaceutical development?

**aktaPD is an international company that partners with academic and governmental institutions and biopharmaceutical and private investment companies to design, develop, and commercialize treatments of diseases. [Click here](#) to see how aktaPD can support you.**



Thanks for the reading 😊 if you like this issue make sure to forward it to your friends.